Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary

NCT00748657 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00748657
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00748657 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
September 22, 2008
Completion date
January 31, 2013
Enrollment
36 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

malignant ovarian epithelial tumor, ovarian granulosa cell tumor, ovarian gynandroblastoma, ovarian sertoli-leydig cell tumor, ovarian sex cord tumor with annular tubules, ovarian sex cord-stromal tumor, ovarian sex cord-stromal tumor of mixed or unclassified cell types, ovarian steroid cell tumor